The Relative Volume value measured for ZIOPHARM Oncology, Inc. stands at 0.61.
Several equities analysts have recently commented on ZIOP shares.
ILLEGAL ACTIVITY WARNING: "ZIOPHARM Oncology (NASDAQ:ZIOP) Earning Somewhat Positive News Coverage, Report Finds" was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. ZIOPHARM Oncology, Inc. (ZIOP) is intriguing when broken down to its core data.
Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Raymond James Financial restated a hold rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th.
When we look at the Analyst Recommendations of the stock, the company has 2.2 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell. $8.25's average target is 100.97% above currents $4.105 stock price.
ZIOPHARM Oncology (ZIOP) opened at $4.38 on Thursday.
The stock is trading -47.59% away from its 52 week high of $7.88 and 9.55% far from the stock's low point over the past 52 weeks, which was $3.77. ZIOPHARM Oncology, Inc. (ZIOP) average trading volume of 1,847,565 during the past month is 30.27% above its average volume over the past year, indicating that investors have been more active than usual in the stock in recent times.
The stock decreased 2.26% or $0.095 during the last trading session, reaching $4.105. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. Its Average True Range (ATR) shows a figure of 0.27. The company's revenue was up.0% compared to the same quarter last year. research analysts predict that ZIOPHARM Oncology will post -0.54 earnings per share for the current year. Accern also assigned news stories about the biotechnology company an impact score of 46.2305854798 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Moreover, Delphi Management Inc Ma has 1.12% invested in the company for 130,480 shares. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
A number of institutional investors and hedge funds have recently bought and sold shares of ZIOP.
Analyst research firms are expressing bullish stance on ZIOPHARM Oncology, Inc. Amalgamated Bank increased its position in ZIOPHARM Oncology by 12.9% during the 2nd quarter. The volume of the company in the last trading session was 845231. Finally, Private Advisor Group LLC lifted its position in ZIOPHARM Oncology by 10.6% during the 2nd quarter.
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.
Penumbra, Inc. (PEN) stock moved with shift of -7.86% in the past week. Finally, Adell Harriman & Carpenter Inc. purchased a new stake in ZIOPHARM Oncology in the third quarter valued at approximately $141,000. BidaskClub upgraded shares of ZIOPHARM Oncology from a "strong sell" rating to a "sell" rating in a report on Thursday, January 4th. With that said, researchers took a deep dive into the hotly debated question: is it too early to buy ZIOPHARM Oncology, Inc. The Company's synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.